<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: Variation in the human <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> (<z:chebi fb="16" ids="53704">APO</z:chebi>) A5 gene (APOA5) is associated with elevated plasma <z:chebi fb="4" ids="17855">triglycerides</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>However, data on the exact role of plasma concentrations of APOA5 in human <z:chebi fb="0" ids="17855">triglyceride</z:chebi> homeostasis are lacking </plain></SENT>
<SENT sid="2" pm="."><plain>In the present study, we estimated plasma APOA5 levels in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> at baseline and during <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> treatment, a <z:chebi fb="23" ids="18059">lipid</z:chebi>-lowering treatment that results in a reduction in plasma <z:chebi fb="4" ids="17855">triglycerides</z:chebi> and APOC3 </plain></SENT>
<SENT sid="3" pm="."><plain>SUBJECTS, MATERIALS AND METHODS: Plasma APOA5 concentration was measured by ELISA in 215 subjects with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, who were taken from the <z:mp ids='MP_0002055'>Diabetes</z:mp> <z:chebi fb="0" ids="39548">Atorvastatin</z:chebi> <z:chebi fb="23" ids="18059">Lipid</z:chebi>-lowering Intervention (DALI) study, a 30-week randomised, double-blind, placebo-controlled study, and given <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> 10 mg or 80 mg daily </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: At baseline, average plasma APOA5 concentration was 25.7+/-15.6 mug/100 ml </plain></SENT>
<SENT sid="5" pm="."><plain>Plasma APOA5 (R (s)=0.40), APOC3 (R (s)=0.72) and APOE (R (s)=0.45) were positively correlated with plasma <z:chebi fb="0" ids="17855">triglyceride</z:chebi> levels (<z:hpo ids='HP_0000001'>all</z:hpo> p&lt;0.001) </plain></SENT>
<SENT sid="6" pm="."><plain>In multiple linear regression analysis, adjusted for age and sex, the variation in plasma <z:chebi fb="4" ids="17855">triglycerides</z:chebi> was explained mostly by APOC3 (52%) and only to a small extent by APOA5 (6%) and APOE (1%) </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="39548">Atorvastatin</z:chebi> treatment decreased plasma <z:chebi fb="4" ids="17855">triglycerides</z:chebi>, APOA5, APOC3 and APOE (<z:hpo ids='HP_0000001'>all</z:hpo> p&lt;0.0001) </plain></SENT>
<SENT sid="8" pm="."><plain>After treatment, APOC3 remained the major determinant of plasma <z:chebi fb="0" ids="17855">triglyceride</z:chebi> levels (59%), while the contributions of APOA5 and APOE were insignificant (2 and 3%) </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS/INTERPRETATION: Our findings reveal a positive association between plasma APOA5 and <z:chebi fb="4" ids="17855">triglycerides</z:chebi> in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="10" pm="."><plain>Treatment with <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> decreased plasma APOA5, APOC3, APOE and <z:chebi fb="4" ids="17855">triglycerides</z:chebi> </plain></SENT>
<SENT sid="11" pm="."><plain>In contrast to APOC3, APOA5 is not a major determinant of <z:chebi fb="0" ids="17855">triglyceride</z:chebi> metabolism in these patients </plain></SENT>
</text></document>